Login / Signup

To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?

Freek de HaanOladimeji Akeem BolarinwaRosemonde GuissouFatoumata TouPaulina TindanaWouter P C BoonEllen H M MoorsPhaik Yeong CheahMehul DhordaArjen M DondorpJean-Bosco OuedraogoOlugbenga A MokuoluChanaki Amaratunga
Published in: PloS one (2021)
The market prospects of TACTs in Nigeria and Burkina Faso will depend on the demonstration of the added value of TACTs over ACTs, their advocacy by the WHO, the inclusion of TACTs in financial and regulatory arrangements, and their alignment with current distribution and deployment practices. Further clinical, health-economic and feasibility studies are required to inform decision makers about the broader implications of a transition to TACTs in African counties. The recent reporting of artemisinin resistance and ACT failure in Africa might change important determinants of the market readiness for TACTs.
Keyphrases